CANF Can-Fite BioPharma Ltd. Total Debt to Capital

Can-Fite BioPharma (CANF) enjoys global recognition for developing safe oral agents against tumors and inflammation. Patent protection of its unique formulas allows the brand to exercise pricing power over its products in the global market. The price history of the separate_debt_total_eq metric at the level of 0.01 completes the business picture, where profit growth depends on licensing agreements due to significant fixed costs.

Investors use this ratio to assess financial stability and the extent of the business's reliance on borrowed funds relative to equity. By analyzing the debt-to-equity trend, one can determine the default risk of Can-Fite BioPharma (CANF), whose strategy for bringing oncology drugs to market requires significant funding for Phase III clinical trials without a critical increase in the debt load.